Four-week Omeprazole Treatment of Non-erosive Reflux Disease in a Japanese Population

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Non-erosive Reflux Disease

Treatments: Drug: Omeprazole

Study type: Interventional

Funder types: Industry

Identifiers

NCT00259077

D9587C00001

D9584L00002

Details and patient eligibility

About

The purpose of this study is to study safety and efficacy of omeprazole standard treatment in a Japanese non-erosive reflux disease population.

Sex: All

Ages: 20+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who identified their predominant symptom as heartburn and were classifiend as Grande M or N according to Hoshihara's modofied version of Los Angeles Classification at esophagogastroduodenoscopy.

Exclusion criteria

• Patients with any ongoing gastrointestinal bleeding at the time of esopgahogastroduodenoscopy, patients with any history of erosive esophagitis or any other major diseases or concommittant drugs likely to interfere with the evaluation of this study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind